Can I Take NAC (N-Acetylcysteine) with Sermorelin?
At a glance
- Interaction studies / none found
- NAC's documented interaction / nitroglycerin [3][4]
- Sermorelin status / Geref discontinued 2008, approvals withdrawn June 2009, compounded today [5][6]
- NAC status / FDA-approved drug since 1963; excluded from the supplement definition [7][8]
- NAC label side effects / nausea, vomiting, stomatitis, fever, drowsiness; bronchospasm with inhaled use [1]
- NAC doses in studies / 600 mg to 3,000 mg a day in respiratory research [9]
- Sermorelin studied doses / 30 mcg/kg nightly in children; 0.5 to 1 mg twice daily in older men [10][11]
- Bottom line / safety of the combination is unknown
Does NAC interact with sermorelin?
The drug-interaction section of the current acetylcysteine prescription label covers one point only: that the stability and safety of mixing acetylcysteine with other drugs in a nebulizer have not been established [1]. Sermorelin has no current label to compare against. Geref was discontinued in 2008 and its two approvals were withdrawn in 2009 [5].
The two drugs act in different ways. Sermorelin binds the pituitary GHRH receptor and triggers release of the body's own growth hormone; it is not growth hormone itself [2]. NAC's labeled pharmacology is its sulfhydryl-driven mucolytic action, and it undergoes rapid deacetylation in the body to yield cysteine or oxidation to diacetylcystine [1]. In a 1993 study of healthy men, an intravenous dose of GHRH(1-29) was rapidly eliminated while growth hormone stayed elevated for about 3 hours [12].
How each one is taken
Sermorelin products sold in the US today are compounded, not FDA-approved; FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed [6]. The studied regimens were subcutaneous: 30 micrograms per kg once daily at bedtime in the pediatric growth program [10], and 0.5 mg or 1 mg twice daily for 14 days in a study of older men [11]. There is no current approved dose [5][6], and those figures are study regimens, not recommendations.
NAC comes as an oral solution, an inhalation solution and an intravenous product [7][1][13]. The label's uses are as an adjuvant mucus thinner in chronic and acute bronchopulmonary disease and, taken by mouth, to prevent or lessen liver injury after a potentially hepatotoxic acetaminophen overdose, with treatment started within 24 hours [1]. A 2021 review notes a maximum licensed chronic dose of 600 mg a day in respiratory medicine; the trials it covered used 600 to 3,000 mg a day, mostly oral [9].
The interaction NAC is actually known for: nitroglycerin
Nitroglycerin is where the clear human data sit, and none of it involves sermorelin.
In 11 healthy volunteers, NAC 100 mg/kg before a nitroglycerin infusion worsened headache (median score 3 versus 1 with placebo) and increased temporal artery dilation to 139% versus 127% of baseline [3]. In a double-blind trial of 200 patients with unstable angina followed for 4 months, death, heart attack or refractory angina occurred in 13% of those given transdermal nitroglycerin plus oral NAC, compared with 31% on nitroglycerin alone, 42% on NAC alone and 39% on placebo. However, 35% of the combination group had side effects, mainly intolerable headache, almost twice as often as with nitroglycerin alone [4]. Laboratory work found that millimolar NAC lowered the nitroglycerin concentration needed to inhibit platelet aggregation about 50-fold, an in-vitro result [14].
What the labels and studies say to watch for
The acetylcysteine label lists nausea, vomiting, stomatitis, fever, rhinorrhea, drowsiness, clamminess, chest tightness and bronchoconstriction, and notes that oral use at the large doses needed for acetaminophen overdose may cause nausea, vomiting and other stomach symptoms; rash with or without mild fever is rare [1]. The label says asthmatics under treatment with acetylcysteine should be watched carefully and that the medication should be discontinued immediately if bronchospasm progresses [1]. It lists sensitivity to acetylcysteine as a contraindication, and says there are no contraindications to oral acetylcysteine for acetaminophen overdose [1].
In the 41-study review in chronic respiratory disease, stomach and gut symptoms were reported at both standard and high doses but were no more common than in control groups [9].
For sermorelin, in a one-year open-label study, 110 previously untreated children were treated and 86 were evaluable for efficacy. No adverse changes appeared in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and it was well tolerated overall [10]. The 14-day study in 10 older men was a physiology experiment and says nothing about long-term safety [11].
Regulatory status of each
NAC has been an FDA-approved new drug since September 14, 1963 [7]. FDA's position is that, because NAC was approved as a drug before it was marketed as a supplement or food, it is excluded from the legal definition of a dietary supplement; in March 2022 FDA denied the request made in two citizen petitions to find otherwise [7][8]. Since August 2022 FDA has said it intends to exercise enforcement discretion for NAC products labeled as supplements that would otherwise be lawful supplements, and a December 2025 warning letter still cites that policy [15][16]. That is a decision not to enforce, not an approval, and FDA's initial review found no safety concerns with NAC in or as a supplement [7][15].
Sermorelin's approvals were Geref NDA 019863 (0.05 mg, a diagnostic test of the pituitary's ability to secrete growth hormone) and NDA 020443 (0.5 mg and 1 mg vials, for idiopathic growth hormone deficiency in children with growth failure) [5]. It was never approved for adults, anti-aging, weight loss or athletic performance [5]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [5]. WADA's 2026 Prohibited List names sermorelin in S2.2.4 and prohibits it at all times, in and out of competition [17].
With Geref withdrawn, sermorelin products in the United States today are compounded and are not FDA-approved [5][6].
Frequently asked questions
Is taking NAC with sermorelin safe?
Does NAC affect growth hormone or IGF-1?
What drugs does NAC interact with?
What are the side effects of oral NAC?
Is sermorelin FDA-approved?
Can I take NAC at the same time as my sermorelin injection?
References
Show all 17 referencesHide references
- U.S. National Library of Medicine, DailyMed. Acetylcysteine oral and inhalation solution prescribing information. Acetylcysteine oral and inhalation solution label
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Iversen HK. N-acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses. Clin Pharmacol Ther. 1992;52(2):125-33.
- Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol. 1997;29(5):941-7.
- Federal Register :: Request Access.
- Official web page.
- U.S. Food and Drug Administration.
- FDA Issues Response to Two Citizen Petitions on NAC in Dietary Supplements | FDA.
- Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf. 2021;44(3):273-290.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
- U.S. National Library of Medicine, DailyMed. Acetadote (acetylcysteine) injection prescribing information. Acetadote (acetylcysteine) injection label
- Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985;76(2):703-8.
- FDA Releases Final Guidance on Enforcement Discretion for Certain NAC Products | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.